FDA unveils framework to curb animal testing in drug developmentApril 11, 2025The U.S. Food and Drug Administration (FDA) aims to replace animal testing with ‘more effective, human-relevant methods’ in developing monoclonal antibody therapies and other drugs.
Education Center - SponsoredRethinking Our Approach to Canine OA: Treating synovial inflammationby • Exubrion TherapeuticsIt’s time to reframe arthritis not just as a painful condition, but as a disease of rampant synovial inflammation. In adopting a proactive treatment strategy that is aimed at modulating the inflammatory process, veterinarians can now provide more effective, long-term care.
FDA conditionally approves feline ventricular hypertrophy medMarch 20, 2025The sirolimus delayed-release tablet is prescribed to help manage ventricular hypertrophy in cats with subclinical hypertrophic cardiomyopathy (HCM).
Broad canine oral parasiticide gets FDA approvalOctober 8, 2024The single monthly dose parasiticide is recommended to protect against six parasites, including fleas, ticks, heartworms, hookworms, and tapeworms.
Canine dermatology drug gets FDA approvalSeptember 19, 2024The once-daily oral JAK inhibitor for control of pruritus associated with allergic dermatitis and control of atopic dermatitis can be prescribed to dogs at least 12 months of age
First generic oral solution for feline hyperthyroidism receives FDA approvalJuly 15, 2024Felanorm, with active ingredient methimazole, is supplied in 30 mL or 100 mL bottles, with a 1 mL dosing syringe for treatment of feline hyperthyroidism.
FDA to host annual educational conferences on Animal Drug User FeeJune 19, 2024The inaugural event on July 17 will cater to stakeholders interested in learning about the U.S. Food and Drug Administration (FDA)'s new animal drug approval process.
